| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 500mg |
|
||
| 1g | |||
| Other Sizes |
| Targets |
HS94 targets death-associated protein kinase 3 (DAPK3), a serine/threonine kinase that plays roles in apoptosis, autophagy, and smooth muscle contraction. DAPK3 is involved in the regulation of blood pressure and vascular tone. HS94 is a selective inhibitor of DAPK3 with a Ki of 126 nM and >20-fold selectivity over Pim kinases, making it a specific tool for studying DAPK3 function.
|
|---|---|
| ln Vitro |
In vitro, HS94 is a selective inhibitor of DAPK3 with a Ki of 126 nM. It exhibits >20-fold selectivity over Pim kinases, confirming its specificity for DAPK3. These in vitro properties make HS94 a valuable tool for studying DAPK3-mediated signaling pathways and their roles in hypertension and other DAPK3-associated conditions. Quantitative in vitro data such as IC50 values are available from biochemical assays.
|
| ln Vivo |
In vivo, HS94 can be used for research of hypertension. As a selective DAPK3 inhibitor, it may modulate blood pressure through effects on vascular smooth muscle contraction. However, detailed in vivo efficacy data are limited in publicly available sources. The compound's potential applications include studying the role of DAPK3 in cardiovascular physiology and hypertension.
|
| Enzyme Assay |
The in vitro enzyme assay for HS94 typically involves measuring its inhibition of DAPK3 kinase activity. The compound is incubated with recombinant DAPK3 enzyme in the presence of ATP and a peptide substrate (e.g., a myosin light chain-derived peptide). Kinase activity is measured using a luminescent or fluorescence-based assay (e.g., ADP-Glo or TR-FRET) to determine the Ki or IC50. Selectivity profiling against Pim kinases and other kinases is performed to confirm specificity.
|
| Cell Assay |
The in vitro cell-based assay for HS94 involves culturing cells that express DAPK3 and treating them with the compound to assess effects on DAPK3-mediated signaling. Cells are treated with HS94 at various concentrations, and DAPK3 activity is assessed by measuring phosphorylation of downstream substrates, such as myosin light chain or other DAPK3 targets, by Western blot. Cell viability and proliferation can also be assessed using MTT or CellTiter-Glo assays to evaluate cytotoxicity.
|
| Animal Protocol |
In vivo animal studies for HS94 have not been extensively reported. If conducted, such studies might involve mouse or rat models of hypertension, where HS94 is administered orally or intraperitoneally and blood pressure is monitored using telemetry or tail-cuff plethysmography. Vascular function and cardiac parameters may also be assessed. Standard protocols for hypertension research would be employed. No specific data are available.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of HS94 have not been extensively characterized. As a small molecule with a molecular weight of 329.38 and a molecular formula of C15H15N5O2S, it is expected to have moderate oral bioavailability. The compound is soluble in DMSO and can be formulated for in vivo administration. Detailed PK parameters such as half-life, Cmax, and bioavailability are not available from publicly accessible sources.
|
| Toxicity/Toxicokinetics |
The toxicity profile of HS94 has not been systematically evaluated. As a research compound targeting DAPK3, its primary safety concerns would relate to on-target effects on apoptosis, autophagy, and smooth muscle function. Standard toxicology assessments would include acute and sub-chronic toxicity studies in rodents, with endpoints including clinical signs, body weight, clinical pathology, and histopathology. No specific toxicity data are available.
|
| References | |
| Additional Infomation |
HS94 is a research compound and has not been approved for clinical use. It is a selective inhibitor of DAPK3 with a Ki of 126 nM and >20-fold selectivity over Pim kinases. HS94 can be used for research of hypertension and is a valuable tool for studying DAPK3-mediated signaling pathways in cardiovascular physiology and disease.
|
| Molecular Formula |
C15H15N5O2S
|
|---|---|
| Molecular Weight |
329.376900911331
|
| Exact Mass |
329.09
|
| Elemental Analysis |
C, 54.70; H, 4.59; N, 21.26; O, 9.71; S, 9.73
|
| CAS # |
1892594-93-2
|
| PubChem CID |
137174459
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
1.5
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
23
|
| Complexity |
530
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(C)(C(=O)N)SC1=NC2=C(C=NN2C3=CC=CC=C3)C(=O)N1
|
| InChi Key |
HIGNONZTHOPLMQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H15N5O2S/c1-15(2,13(16)22)23-14-18-11-10(12(21)19-14)8-17-20(11)9-6-4-3-5-7-9/h3-8H,1-2H3,(H2,16,22)(H,18,19,21)
|
| Chemical Name |
2-methyl-2-((4-oxo-1-phenyl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-yl)thio)propanamide
|
| Synonyms |
HS94; HS-94; HS 94; DAPK3 inhibitor HS94;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0360 mL | 15.1800 mL | 30.3601 mL | |
| 5 mM | 0.6072 mL | 3.0360 mL | 6.0720 mL | |
| 10 mM | 0.3036 mL | 1.5180 mL | 3.0360 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
